{"schema_version":"1.0","type":"article","title":"投資人請注意，給藥方式是藍海！","url":"https://drugnews.com.tw/articles/2026-04-24-dcard-261359193.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-24-dcard-261359193.md","lang":"zh-Hant","date":"2026-04-24","publish_at":"2026-04-24T10:30:00+08:00","updated_at":"2026-04-24","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資","製藥巨頭"],"summary":"這幾年，如果你把跨國藥廠的動作連起來看，會發現一個非常一致、幾乎帶著戰略共識的方向：把原本靠靜脈輸注（IV）的重磅生物藥，盡可能改造成皮下注射（SC）版本。","key_points":[],"facts":[],"sections":["大藥廠為何集體把生物藥推向皮下？未來 3 到 5 年，真正的大藍海可能不在分子本身，而在給藥方式"],"references":[{"title":"[0]:各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab) - Merck.com","source":"","date":"","url":""},{"title":"KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced tha","source":"","date":"","url":""},{"title":"www.merck.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial - Merck.com","source":"","date":"","url":""},{"title":"Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemo","source":"","date":"","url":""},{"title":"www.merck.com","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"ENHANZE Drug Delivery Technology","source":"Halozyme","date":"","url":""},{"title":"https://halozyme.com/drug-delivery-technologies/enhanze/partners.php","source":"","date":"","url":"https://halozyme.com/drug-delivery-technologies/enhanze/partners.php"},{"title":"halozyme.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of DARZALEX® (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma","source":"","date":"","url":""},{"title":"https://www.jnj.com/media-center/press-releases/phase-3-columba-study-investigating-a-subcutaneous-formulation-of-darzalex-daratumumab-showed-non-inferiority-to-intravenous-administration-in-patients-with-relapsed-refractory-multiple-myeloma","source":"","date":"","url":"https://www.jnj.com/media-center/press-releases/phase-3-columba-study-investigating-a-subcutaneous-formulation-of-darzalex-daratumumab-showed-non-inferiority-to-intravenous-administration-in-patients-with-relapsed-refractory-multiple-myeloma"},{"title":"www.jnj.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"Genentech: Press Releases","source":"Thursday, Feb 28, 2019","date":"","url":""},{"title":"Discover the latest news about our company, our products, our policies, and our people.","source":"","date":"","url":""},{"title":"www.gene.com","source":"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"Lock","source":"","date":"","url":""},{"title":"Subcutaneous (SC) delivery of biologics has traditionally been limited to fluid volumes of 1–2 mL, with recent increases to volumes of about 3 mL. This injection volume limitation poses challenges for high-dose biologics, as these formulations may ...","source":"","date":"","url":""},{"title":"![Dcard 原圖：投資人請注意，給藥方式是藍海！（圖 2）](images/dcard-02.webp","source":"","date":"","url":""},{"title":"pmc.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"[7]:","source":"","date":"","url":""},{"title":"FDA Approval Received for EMPAVELI Injector","source":"Enable Injections","date":"","url":""},{"title":"Enable Injections' EMPAVELI Injector (enFuse®) receives FDA approval for subcutaneous delivery of EMPAVELI® (pegcetacoplan), enhancing at-home self-administration for PNH patients.","source":"","date":"","url":""},{"title":"enableinjections.com","source":"","date":"","url":""},{"title":"[8]:","source":"","date":"","url":""},{"title":"Who Are We – Subcutaneous Drug Development & Delivery Consortium","source":"","date":"","url":""},{"title":"https://subcutaneousconsortium.org/who-are-we/","source":"","date":"","url":"https://subcutaneousconsortium.org/who-are-we/"},{"title":"subcutaneousconsortium.org","source":"","date":"","url":""},{"title":"[9]:","source":"","date":"","url":""},{"title":"arecor.com","source":"","date":"","url":""},{"title":"https://arecor.com/wp-content/uploads/2025/05/2025-05-19-ARECOR-ESTABLISHES-PARTNERSHIP-WITH-SKYE-BIOSCIENCE.pdf","source":"","date":"","url":"https://arecor.com/wp-content/uploads/2025/05/2025-05-19-ARECOR-ESTABLISHES-PARTNERSHIP-WITH-SKYE-BIOSCIENCE.pdf"},{"title":"arecor.com","source":"","date":"","url":""},{"title":"[10]:","source":"","date":"","url":""},{"title":"Enable Injections","source":"High-Volume Wearable Drug Delivery Systems","date":"","url":""},{"title":"Enable Injections specializes in high-volume wearable drug delivery systems. Creators of the enFuse® On-Body Platform. Drug delivery redefined.","source":"","date":"","url":""},{"title":"enableinjections.com","source":"","date":"","url":""},{"title":"[11]:","source":"","date":"","url":""},{"title":"알테오젠 ALTEOGEN","source":"","date":"","url":""},{"title":"https://alteogen.com/en/sub/ir/news.php","source":"","date":"","url":"https://alteogen.com/en/sub/ir/news.php"},{"title":"alteogen.com","source":"","date":"","url":""},{"title":"[12]:","source":"","date":"","url":""},{"title":"![Dcard 原圖：投資人請注意，給藥方式是藍海！（圖 3）](images/dcard-03.png","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：投資人請注意，給藥方式是藍海！（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261359193/dcard-01.webp"},{"alt":"Dcard 原圖：投資人請注意，給藥方式是藍海！（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261359193/dcard-02.webp"},{"alt":"Dcard 原圖：投資人請注意，給藥方式是藍海！（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261359193/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261359193/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-24）。投資人請注意，給藥方式是藍海！。https://drugnews.com.tw/articles/2026-04-24-dcard-261359193.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-24-dcard-261359193-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}